Drug Profile
TL 3024
Latest Information Update: 26 Mar 2007
Price :
$50
*
At a glance
- Originator Torii Pharmaceutical
- Class Antivirals
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 31 Oct 2006 Discontinued - Preclinical for Influenza virus infections in Japan (unspecified route)
- 04 Sep 1998 No-Development-Reported for Influenza virus infections in Japan (Unknown route)
- 28 Sep 1995 Preclinical development for Influenza virus infections in Japan (Unknown route)